DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Meningococcal Vaccine Market By Brand, By Type, By Age Group, By Country, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

The Asia Pacific Meningococcal Vaccine Market is expected to witness market growth of 9.9% CAGR during the forecast period (2020-2026).

Meningococcal vaccine manufacturers are focusing on the Asia Pacific region in order to capitalize for broadening treatment options for meningococcal disease in the region. As polysaccharide vaccines continue to show high traction from emerging countries owing to limited supply by limited vaccine manufacturers. That is why market forerunners team up with local distributors in order to expand their footprint. Furthermore, key market players, such as GlaxoSmithKline Plc., are capitalizing more to widening the range of age covered by meningococcal vaccines in the market.

The transmission of meningococcal bacteria, and unpredictable occurrences over time and across different age groups and geographies, have resulted in a substantial increase in the number of clinical programs for the effective development of meningococcal vaccines across the globe. Presently, around 30 ongoing clinical programs for the development of meningococcal vaccines at different stages. In the context of increasing government initiatives towards the development of meningococcal vaccines, the potential demand for these vaccines has increased.

Based on Brand, the market is segmented into Bexsero, Trumenba, Nimenrix, Menactra, Menveo and Other Brands. Based on Type, the market is segmented into Bivalent, Quadrivalent and Other Types. Based on Age Group, the market is segmented into Infants (0 to 2 years) and Children (2 years & above). Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market.

Scope of the Study

Market Segments covered in the Report:

By Brand

• Bexsero
• Trumenba
• Nimenrix
• Menactra
• Menveo
• Other Brands

By Type

• Bivalent
• Quadrivalent
• Other Types

By Age Group

• Infants (0 to 2 years)
• Children (2 years & above)

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Companies Profiled

• GlaxoSmithKline PLC (GSK)
• Pfizer, Inc.
• Sanofi S.A.
• Walvax Biotechnology Co., Ltd.
• Bio-Manguinhos (Oswaldo Cruz Foundation)
• Bio-Med Pvt. Ltd.
• Chongqing Zhifei Biological Products Co., Ltd.
• Hualan Biological Engineering, Inc.
• Incepta Pharmaceuticals Ltd.
• Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)

For more information about this report visit https://www.researchandmarkets.com/r/2ntia9

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900